Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the latest fitness gadgets, testing out activewear and sneakers, as well as debunking wellness/fitness myths. In my free time I enjoy ...
Vanessa is a lead writer at CNET, reviewing and writing about the latest smartwatches and fitness trackers. She joined the brand first as an on-camera reporter for CNET's Spanish-language site, then ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback